Evidence map›Paper›PMID 26279137›Full record

ArticleBone2015

Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.

Marie-Therese Haider, Keith D Hunter, Simon P Robinson, Timothy J Graham, Eva Corey, T Neil Dear, Russell Hughes, Nicola J Brown, Ingunn Holen

Open access · hybridAbstract read
In one paragraph

Article in Bone, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Macrophage-Derived Vascular Endothelial Growth Factor-A Is Integral to Neuromuscular Junction Reinnervation after Nerve Injury.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Marie-Therese HaiderDepartment of Oncology, University of Sheffield, Sheffield, UK. Electronic address: mhaider1@sheffield.ac.uk.
Keith D HunterSchool of Clinical Dentistry, University of Sheffield, Sheffield, UK. Electronic address: k.hunter@sheffield.ac.uk.
Simon P RobinsonCR-UK Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: Simon.Robinson@icr.ac.uk.
Timothy J GrahamCR-UK Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, Surrey, UK. Electronic address: timothy.graham@icr.ac.uk.
Eva CoreyDepartment of Urology, University of Washington Medical Center, Seattle, WA, USA. Electronic address: ecorey@uw.edu.
T Neil DearSouth Australian Health and Medical Research Institute, Adelaide, SA, Australia. Electronic address: neil.dear@sahmri.com.
Russell HughesDepartment of Oncology, University of Sheffield, Sheffield, UK. Electronic address: r.hughes@sheffield.ac.uk.
Nicola J BrownDepartment of Oncology, University of Sheffield, Sheffield, UK. Electronic address: n.j.brown@sheffield.ac.uk.
Ingunn HolenDepartment of Oncology, University of Sheffield, Sheffield, UK. Electronic address: I.Holen@Sheffield.ac.uk.
University of Sheffield · GBInstitute of Cancer Research · GBSouth Australian Health and Medical Research Institute · AUUniversity of Washington Medical Center · US

Funding

Cancer Research UK 16464Cancer Research UK C1060/A10334
6 · The paper itself

Abstract

introductionBone metastasis remains incurable with treatment restricted to palliative care. Cabozantinib (CBZ) is targeted against multiple receptor tyrosine kinases involved in tumour pathobiology, including hepatocyte growth factor receptor (MET) and vascular endothelial growth factor receptor 2 (VEGFR-2). CBZ has demonstrated clinical activity in advanced prostate cancer with resolution of lesions visible on bone scans, implicating a potential role of the bone microenvironment as a mediator of CBZ effects. We characterised the effects of short-term administration of CBZ on bone in a range of in vivo models to determine how CBZ affects bone in the absence of tumour.

methodsStudies were performed in a variety of in vivo models including male and female BALB/c nude mice (age 6-17-weeks). Animals received CBZ (30 mg/kg, 5× weekly) or sterile H2O control for 5 or 10 days. Effects on bone integrity (μCT), bone cell activity (PINP, TRAP ELISA), osteoblast and osteoclast number/mm trabecular bone surface, area of epiphyseal growth plate cartilage, megakaryocyte numbers and bone marrow composition were assessed. Effects of longer-term treatment (15-day & 6-week administration) were assessed in male NOD/SCID and beige SCID mice.

resultsCBZ treatment had significant effects on the bone microenvironment, including reduced osteoclast and increased osteoblast numbers compared to control. Trabecular bone structure was altered after 8 administrations. A significant elongation of the epiphyseal growth plate, in particular the hypertrophic chondrocyte zone, was observed in all CBZ treated animals irrespective of administration schedule. Both male and female BALB/c nude mice had increased megakaryocyte numbers/mm(2) tissue after 10-day CBZ treatment, in addition to vascular ectasia, reduced bone marrow cellularity and extravasation of red blood cells into the extra-vascular bone marrow. All CBZ-induced effects were transient and rapidly lost following cessation of treatment.

conclusionShort-term administration of CBZ induces rapid, reversible effects on the bone microenvironment in vivo highlighting a potential role in mediating treatment responses.

Indexed as

AnilidesAnimalsBone and BonesBone MarrowBone NeoplasmsBone RemodelingCellular MicroenvironmentFemaleGrowth PlateMaleMiceMice, Inbred BALB CMice, NudeMice, TransgenicOsteoblastsOsteoclastsAnilidescabozantinibProtein Kinase InhibitorsPyridinesReceptor Protein-Tyrosine KinasesBone marrowBone microenvironmentOsteoblastOsteoclastVasculature

Identifiers

PMID26279137
PMCPMC4768060
OpenAlexW1145491420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.